IMMY on 2015 Inc. 5000 list
Copyright © 2015 IMMY
IMMY has been named one of Inc. Magazine’s Fastest Growing Private Companies in America for 2015. Over the past few years, IMMY has recorded revenue growth of 128 percent, with 2014 gross revenue of $6.5M.
The Inc. 5000 list measures revenue growth from 2011 to 2014. To qualify, companies must have been founded and generating revenue by March 31, 2011. Additionally, they had to be U.S.-based, privately held, for profit, and independent (not subsidiaries or divisions of other companies) as of December 31, 2014.
“This is a huge honor for IMMY and all of our amazing employees,” said Dr. Sean Bauman, President and CEO. “To receive an award like this is definitely a credit to the hard work everyone puts in each and every day in carrying out the vision that’s been in place from the beginning: Saving lives one diagnostic at a time.”
IMMY, a diagnostic manufacturing company, has evolved from a company that filled a need in the infectious disease market to an organization with a global focus on saving lives through innovative products. Along with ever-increasing sales in the U.S., the scope of IMMY’s global impact has seen tremendous growth with products going to over 100 different countries.
IMMY’s most successful product to date, the CrAg® LFA, tests for an infection called Cryptococcosis, which kills more than 600,000 people every year. Most of the deaths from this disease are HIV/AIDS patients in Sub-Saharan Africa. Because of the ease-of-use and room temperature storage, the CrAg® LFA is the only rapid test capable of bridging the gap between this disease and the life-saving medicine these patients need.
“Our goal is to save lives,” said Dr. Bauman. “With the CrAg LFA, a health-care provider can give the test, observe the results, and administer the first dose of oral medication, all within a few minutes…resulting in a life that has truly been changed for the better.”